This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc., a leader in the regenerative medicine industry, is headquartered in the United States and operates across key regions globally. Founded in 2008, the company has made significant strides in developing innovative therapies that harness the body’s natural healing processes. Shire focuses on advanced cell and gene therapies, offering unique products that address unmet medical needs in areas such as orthopaedics and wound care. Their commitment to research and development has positioned them as a notable player in the regenerative medicine market, with a reputation for pioneering solutions that enhance patient outcomes. With a strong emphasis on scientific excellence and patient-centric approaches, Shire Regenerative Medicine continues to set benchmarks in the industry, driving forward the future of healing and recovery.
DitchCarbon Score
How does Shire Regenerative Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire Regenerative Medicine, Inc.'s score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire Regenerative Medicine, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which cascades its climate commitments and emissions data down to Shire. As part of its climate strategy, Shire follows the initiatives set by Takeda, which includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Shire are not detailed in the available information. Shire's climate commitments are aligned with industry standards, reflecting a broader commitment to sustainability and carbon reduction within the pharmaceutical sector. The absence of direct emissions data suggests that Shire is in the process of developing its own reporting framework, potentially influenced by the practices of its parent company, Takeda.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire Regenerative Medicine, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
